Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules

Patent metadata

Field	Value
Publication number	US-10183987-B2
Application number	US-201715684595-A
Country	US
Kind code	B2
Filing date	Aug 23, 2017
Priority date	Nov 24, 2008
Publication date	Jan 22, 2019
Grant date	Jan 22, 2019

Abstract

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

First claim

We claim:

1. A nucleic acid encoding a protein consisting of a tenth fibronectin type III domain ( 10 Fn3) that binds epidermal growth factor receptor (EGFR) with a K D of less than 500 nM, wherein the 10 Fn3 comprises a BC loop having the amino acid sequence X g WAPVDRYQX h (SEQ ID NO: 137), a DE loop having the amino acid sequence X i RDVYX j (SEQ ID NO: 138), and an FG loop having the amino acid sequence X k DYKPHADGPHTYHESX l (SEQ ID NO: 139); and wherein X is any amino acid and g, h, i, j, k, and 1 are integers independently selected from 0 to 5.

2. The nucleic acid of claim 1 , wherein the 10 Fn3 comprises a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117).

3. The nucleic acid of claim 1 , wherein the 10 Fn3 domain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 112.

4. The nucleic acid of claim 1 , wherein the 10 Fn3 domain comprises an amino acid sequence at least 95% identical to SEQ ID NO: 112.

5. The nucleic acid of claim 1 , wherein the 10 Fn3 domain comprises an amino acid sequence at least 98% identical to SEQ ID NO: 112.

6. The nucleic acid of claim 5 , wherein the 10 Fn3 domain comprises the amino acid sequence of SEQ ID NO: 112.

7. The nucleic acid of claim 1 , wherein the 10 Fn3 comprises the amino acid sequence of SEQ ID NOs: 112-114.

8. A vector comprising the nucleic acid of claim 1 .

9. An isolated host cell comprising the nucleic acid of claim 1 .

10. A nucleic acid encoding a protein consisting of a tenth fibronectin type III domain ( 10 Fn3) that binds EGFR with a K D of less than 500 nM, wherein the EGFR binding 10 Fn3 comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 112.

11. A nucleic acid encoding a protein comprising the amino acid sequence of SEQ ID NO: 130.

12. A vector comprising the nucleic acid of claim 11 .

13. An isolated host cell comprising the nucleic acid of claim 11 .

Assignees

• Bristol Myers Squibb Co

Inventors

• Emanuel Stuart
• Engle Linda
• Camphausen Ray
• Wright Martin C
• Rakestraw Ginger Chao
• Gottardis Marco
• Carboni Joan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title